Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+75.7%
5Y CAGR+77.8%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+75.7%/yr
vs +183.9%/yr prior
5Y CAGR
+77.8%/yr
Consistent
Acceleration
-108.1pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
17.8x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$475.36M+63.5%
2024$290.70M+82.8%
2023$159.01M+81.6%
2022$87.57M+30.5%
2021$67.11M+151.0%
2020$26.74M+533.0%
2019$4.22M+213.1%
2018$1.35M-